[Form 4] Alkermes plc. Insider Trading Activity

Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported equity compensation activity in the company’s ordinary shares.

Rhea-AI Filing Summary

Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported equity compensation activity in the company’s ordinary shares. On February 5, 2026, he acquired 25,352 ordinary shares at no cost upon vesting of performance-vesting restricted stock units granted on February 23, 2023.

The vesting followed achievement of pre-set performance goals and application of a relative total shareholder return modifier, and represents the final vesting event under the 2023 PRSU awards. On the same date, 7,454 shares were disposed of at $33.55 per share (code F), typically indicating shares withheld or sold to cover tax obligations, leaving 75,638 shares held directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hopkinson Craig C.

Role EVP R&D, Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	25,352	$0.00	$0.00
Exercise Price or Tax Liability	Ordinary Shares	7,454	$33.55	$250K

Holdings After Transaction: Ordinary Shares — 75,638 shares (Direct)

Footnotes (1)

1. F1. These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 23, 2023 with a three-year performance period that ended on December 31, 2025 (the "2023 PRSUs"). The vesting of this portion of the 2023 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a relative total shareholder return modifier and represents the final vesting event under the 2023 PRSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alkermes (ALKS) report for Craig C. Hopkinson?

Craig C. Hopkinson reported equity compensation activity in Alkermes shares. He received 25,352 ordinary shares from vesting performance-based RSUs and disposed of 7,454 shares at $33.55, ending with 75,638 shares held directly.

How many Alkermes (ALKS) shares did Craig C. Hopkinson acquire and at what cost?

He acquired 25,352 Alkermes ordinary shares at no cash cost. These shares came from vesting performance-vesting restricted stock units granted in February 2023 after a three-year performance period ending December 31, 2025.

Why did Craig C. Hopkinson receive Alkermes (ALKS) shares from the 2023 PRSUs?

The shares were issued because performance goals under 2023 PRSUs were achieved. Vesting was triggered by achievement of specified performance targets and a relative total shareholder return modifier, marking the final vesting event for the 2023 PRSU awards.

What does transaction code “F” mean in Craig C. Hopkinson’s Alkermes (ALKS) Form 4?

The Form 4 shows a code “F” disposition of 7,454 shares at $33.55. Code F typically reflects shares withheld or sold to satisfy tax obligations related to equity award vesting, while leaving the remaining net shares directly owned.

How many Alkermes (ALKS) shares does Craig C. Hopkinson own after these transactions?

After the reported transactions, he directly owns 75,638 Alkermes ordinary shares. This reflects the net result of 25,352 shares received from vesting awards and 7,454 shares disposed of at $33.55 on February 5, 2026.

What is the performance period for Craig C. Hopkinson’s 2023 Alkermes (ALKS) PRSUs?

The 2023 performance-vesting RSUs had a three-year performance period. They were granted on February 23, 2023, with performance measured through December 31, 2025, and this filing reflects the final vesting event under that grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 07:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkinson Craig C.

(Last) (First) (Middle)

900 WINTER ST.

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP R&D, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/05/2026		A		25,352	A	(1)	83,092	D
Ordinary Shares	02/05/2026		F		7,454	D	$33.55	75,638	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 23, 2023 with a three-year performance period that ended on December 31, 2025 (the "2023 PRSUs"). The vesting of this portion of the 2023 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a relative total shareholder return modifier and represents the final vesting event under the 2023 PRSUs.

	/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.